Management of hypertension in diabetes mellitus

References

• Arauz-Pacheco C. Management of hypertension in adults with diabetes: ADA Clinical Practice Recommendations 2002. Diabetes Care25(Suppl 1), 134–147 (2002).
   PubMed Web of Science ®Google Scholar
• Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988–1994. Am. J. Prev. Med.22(1), 42–48 (2002).
   PubMed Web of Science ®Google Scholar
• Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens.11(3), 309–317 (1993).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br. Med. J.316(7134), 823–828 (1998).
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. Br. Med. J.321(7258), 412–419 (2000).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J.317(7160), 703–713 (1998).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med.340(9), 677–684 (1999).
   PubMed Web of Science ®Google Scholar
• Curb J, Pressel S, Cutler J et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA276(23), 1886–1892 (1996).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345(12), 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med.345(12), 870–878 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345(12), 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet355(9200), 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet351(9118), 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care23(Suppl. 2), B54–B64 (2000).
   PubMed Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med.338(10), 645–652 (1998).
   PubMed Web of Science ®Google Scholar
• Tatti P. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care21(4), 597–603 (1998).
   PubMed Web of Science ®Google Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br. Med. J.317(7160), 713–720 (1998).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm L, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet353(9153), 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med.348(7), 583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet354(9192), 1751–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet356(9227), 359–365 (2000).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA290(21), 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Gaxiola E, Messerli FH et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension44(5), 637–642 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Brown M, Palmer C, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet356(9227), 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Julius S, Weber MA, Kjeldsen SE et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension48(3), 385–391 (2006).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Julius S, Kjeldsen S et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J. Hypertens.24(11), 2163–2168 (2006).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs64(Suppl. 2), 43–60 (2004).
   PubMed Web of Science ®Google Scholar
• Savage S, Johnson Nagel N, Estacio RO et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in Type II diabetes. Online J. Curr. Clin. Trials (1993) (Doc. No. 104).
   Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Shankar A, Klein R, Klein BE, Nieto FJ, Moss SE. Relationship between low-normal blood pressure and kidney disease in Type 1 diabetes. Hypertension49(1), 48–54 (2007).
   Google Scholar
• Weir MR. How do you define “hypertension” in a patient withType 1 diabetes? Hypertension49(1), 13–14 (2007).
   Google Scholar
• Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J. Am. Soc. Nephrol.16(10), 3027–3037 (2005).
   PubMed Web of Science ®Google Scholar
• Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol.16(7), 2170–2179 (2005).
   PubMed Web of Science ®Google Scholar
• Maahs DM, Kinney GL, Wadwa P et al. Hypertension prevalence, awareness, treatment, and control in an adult Type 1 diabetes population and a comparable general population. Diabetes Care28(2), 301–306 (2005).
   PubMed Web of Science ®Google Scholar
• Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension19(5), 403–418 (1992).
   PubMed Web of Science ®Google Scholar
• O’Hare JA, Ferriss JB, Brady D, Twomey B, O’Sullivan DJ. Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension7(6 Pt 2), II43–II48 (1985).
   PubMedGoogle Scholar
• de Chatel R, Weidmann P, Flammer J et al. Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. Kidney Int.12(6), 412–421 (1977).
   PubMedGoogle Scholar
• Eriksson H, Welin L, Wilhelmsen L et al. Metabolic disturbances in hypertension: results from the population study ‘men born in 1913’. J. Intern. Med.232(5), 389–395 (1992).
   Google Scholar
• Morse SA, Zhang R, Thakur V, Reisin E. Hypertension and the metabolic syndrome. Am. J. Med. Sci.330(6), 303–310 (2005).
   Web of Science ®Google Scholar
• Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care27(10), 2444–2449 (2004).
   PubMed Web of Science ®Google Scholar
• Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care28(11), 2745–2749 (2005).
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis173(2), 309–314 (2004).
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care14(Suppl. 4), 13–26 (1991).
   PubMed Web of Science ®Google Scholar
• Randeree HA, Omar MA, Motala AA, Seedat MA. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care15(10), 1258–1263 (1992).
   PubMed Web of Science ®Google Scholar
• Nosadini R, Sambataro M, Thomaseth K et al. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int.44(1), 139–146 (1993).
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. Relation between aortic atherosclerosis and blood pressure. Lancet343(8905), 1107 (1994).
   Google Scholar
• DeFronzo RA. Insulin and renal sodium handling: clinical implications. Int. J. Obes.5(Suppl. 1), 93–104 (1981).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J. Clin. Invest.55(4), 845–855 (1975).
   PubMed Web of Science ®Google Scholar
• Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes30(3), 219–225 (1981).
   PubMed Web of Science ®Google Scholar
• Larger E. Weight gain and insulin treatment. Diabetes Metab.31(4 Pt 2), 4S51–54S56 (2005).
   Google Scholar
• Chuang SY, Chou P, Hsu PF et al. Presence and progression of abdominal obesity are predictors of future high blood pressure and hypertension. Am. J. Hypertens.19(8), 788–795 (2006).
   PubMed Web of Science ®Google Scholar
• Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation106(16), 2085–2090 (2002).
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Lim HS. Emergence of structural arterial stiffness in diabetes and the role of abnormalities of autonomic tone in the sequence of events. J. Hum. Hypertens.18(11), 755–756 (2004).
   Google Scholar
• Strain WD, Chaturvedi N, Dockery F et al. Increased arterial stiffness in Europeans and African Caribbeans with Type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors. Am. J. Hypertens.19(9), 889–896 (2006).
   PubMed Web of Science ®Google Scholar
• Stamler R, Stamler J, Grimm R et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial – the Hypertension Control Program. JAMA257(11), 1484–1491 (1987).
   PubMed Web of Science ®Google Scholar
• Stamler R, Grimm RH Jr, Dyer AR et al. Cardiac status after four years in a trial on nutritional therapy for high blood pressure. Arch. Intern. Med.149(3), 661–665 (1989).
   PubMedGoogle Scholar
• Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation91(3), 698–706 (1995).
   PubMed Web of Science ®Google Scholar
• Grimm RH Jr, Flack JM, Grandits GA et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA275(20), 1549–1556 (1996).
   PubMed Web of Science ®Google Scholar
• Staessen J, Fagard R, Lijnen P, Amery A. Body weight, sodium intake and blood pressure. J. Hypertens. Suppl.7(1), S19–S23 (1989).
   Google Scholar
• Cutler JA, Follmann D, Elliott P, Suh I. An overview of randomized trials of sodium reduction and blood pressure. Hypertension17(1 Suppl.), I27–I33 (1991).
   PubMedGoogle Scholar
• Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am. J. Clin. Nutr.65(2 Suppl.), S643–S651 (1997).
   PubMed Web of Science ®Google Scholar
• Vollmer W, Sacks F, Ard J et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-Sodium Trial. Ann. Intern. Med.135(12), 1019–1028 (2001).
   PubMed Web of Science ®Google Scholar
• Schotte D, Stunkard A. The effects of weight reduction on blood pressure in 301 obese patients. Arch. Intern. Med.150(8), 1701–1704 (1990).
   PubMed Web of Science ®Google Scholar
• Kawabe H, Saito I, Saruta T. Effects of nighttime alcohol intake on evening and next morning home blood pressure in Japanese normotensives. Clin. Exp. Hypertens.29(1), 43–49 (2007).
   PubMed Web of Science ®Google Scholar
• Kodavali L, Townsend RR. Alcohol and its relationship to blood pressure. Curr. Hypertens. Rep.8(4), 338–344 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Safi SA. Does smoking affect blood pressure and heart rate? Eur. J. Cardiovasc. Nurs.4(4), 286–289 (2005).
   PubMedGoogle Scholar
• Moore TJ, McKnight JA. Dietary factors and blood pressure regulation. Endocrinol. Metab. Clin. North Am.24(3), 643–655 (1995).
   Google Scholar
• McKnight JA, Moore TJ. The effects of dietary factors on blood pressure. Compr. Ther.20(9), 511–517 (1994).
   PubMedGoogle Scholar
• Dickinson HO, Mason JM, Nicolson DJ et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J. Hypertens.24(2), 215–233 (2006).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes – 2007. Diabetes Care30(Suppl. 1), S4–S41 (2007).
   PubMedGoogle Scholar
• He J. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet356(9246), 1955–1964 (2000).
   Google Scholar
• Perry HM Jr, Davis BR, Price TR et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA284(4), 465–471 (2000).
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J.28(1), 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA283(15), 1967–1975 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet353(9153), 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Poulter NR, Wedel H, Dahlof B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet366(9489), 907–913 (2005).
   PubMed Web of Science ®Google Scholar
• Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA271(4), 275–279 (1994).
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet349(9068), 1787–1792 (1997).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med.329(20), 1456–1462 (1993).
   PubMed Web of Science ®Google Scholar
• Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Remission and regression in the nephropathy of Type 1 diabetes when blood pressure is controlled aggressively. Kidney Int.60(1), 277–283 (2001).
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int.63(5), 1874–1880 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type I diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol.14(4), 992–999 (2003).
   PubMed Web of Science ®Google Scholar
• Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med.128(12 Pt 1), 982–988 (1998).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int.61(3), 1086–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med.351(19), 1952–1961 (2004).
   Google Scholar
• Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J. Am. Soc. Nephrol.16(10), 3081–3091 (2005).
   Google Scholar
• Elliott WJ, Weir DR, Black HR. Cost–effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med.160(9), 1277–1283 (2002).
   Google Scholar
• Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension5(5 Pt 2), III132–III138 (1983).
   PubMedGoogle Scholar
• MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am. J. Kidney Dis.48(1), 8–20 (2006).
   PubMed Web of Science ®Google Scholar
• Ostergren J. Renin–angiotensin-system blockade in the prevention of diabetes. Diabetes Res. Clin. Pract.76(3 Suppl.), S13–S21 (2007).
   Google Scholar
• Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA286(15), 1882–1885 (2001).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens.20(9), 1879–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens.22(8), 1605–1612 (2004).
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med.355(15), 1551–1562 (2006).
   PubMed Web of Science ®Google Scholar
• Ingelfinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance – is there still hope? N. Engl. J. Med.355(15), 1608–1610 (2006).
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369(9557), 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care29(12), 2592–2597 (2006).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA292(18), 2227–2236 (2004).
   PubMed Web of Science ®Google Scholar